Allyx Therapeutics, Inc.
About Allyx Therapeutics, Inc.
Allyx Therapeutics, Inc. is a clinical-stage biotechnology company based in New Haven, Connecticut, developing novel therapies for Alzheimer’s disease and other neurodegenerative diseases. Its approach focuses on protecting synapses, the connections between neurons that support memory and cognitive function. The company’s lead candidate, ALX-001, is an oral small molecule designed to block harmful signaling associated with synapse loss while preserving normal glutamate signaling at mGluR5. It has in-licensed the mGluR5 program from Bristol Myers Squibb and Yale University and has leveraged non-dilutive grants from NIA, NIH, and other organizations.
- 🔗 NIA Small Business Showcase: Allyx Therapeutics, Inc. | National Institute on Aging
- 🔗 Allyx Therapeutics | Alzheimer's Drug Discovery Foundation
- 🔗 After raising $62M, New Haven biotech Allyx Therapeutics advances experimental Alzheimer’s drug
- 🔗 Allyx Therapeutics Stock Price, Funding, Valuation, Revenue & Financial Statements
- 🔗 Allyx Therapeutics | SPRIM Global Investments
Investors
Key highlights
- Raised $27.9M via private placement after earlier Series A and Series B rounds.
- Lead asset ALX-001 is a first-in-class oral mGluR5 modulator for synapse protection in Alzheimer’s.
- Secured nearly $12M in non-dilutive grants from NIH, NIA, Michael J. Fox Foundation and Alzheimer’s Association.
- In-licensed mGluR5 program from Bristol Myers Squibb and Yale University in 2021.
- Elm Street Ventures led Series A and holds a board seat.
Ask StreetZero about Allyx Therapeutics, Inc.
Put our AI to work on this deal.
Similar companies
Other Biotechnology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account